Defining the Role of Monocytes in Sjogren's Syndrome

Sjogren's syndrome is one of the most prevalent autoimmune diseases after rheumatoid arthritis, with a preference for middle age, and is characterised by exocrine glandular involvement leading to xerostomia and xerophthalmia. It can have systemic implications with vascular, neurological, renal, and pulmonary involvement, and in some cases, it may evolve to non-Hodgkin's lymphoma. For a long time, B- and T-lymphocytes have been the focus of research and have been considered key players in Sjogren's syndrome pathogenesis and evolution. With the development of new technologies, including omics, more insights have been found on the different signalling pathways that lead to inflammation and activation of the immune system. New evidence indicates that a third actor linking innate and adaptive immunity plays a leading role in the Sjogren's syndrome play: the monocyte. This review summarises the recent insights from transcriptomic, proteomic, and epigenetic studies that help us to understand more about the Sjogren's syndrome pathophysiology and redefine the involvement of monocytes in this disease.

Automated summary

Sjogren's syndrome is a common autoimmune disease characterized by dry mouth and eyes, and can involve multiple systems. Previous research has focused on the role of B cells and T cells in the pathogenesis and progression of Sjogren's syndrome. However, recent studies have identified monocytes as a third player connecting innate and adaptive immunity in this disease.